Semisynthetic opiates provide some of the most potent analgesic compounds currently in clinical use, the majority of which are synthesized from the naturally occurring alkaloids morphine, codeine and thebaine. The use of recombinant DNA technology to engineer pathways for the biological synthesis of semisynthetic opiate drugs could offer significant advantages over existing chemical methods and may, ultimately, provide novel biosynthetic routes for the development of new therapeutics.
|Number of pages||6|
|Journal||Trends in biotechnology|
|Publication status||Published - Jun 1995|